Skip to main content Skip to search Skip to main navigation

PIC/S: Guidance on Remote Assessments

PIC/S has published two guidance documents for inspectors: "Guidance on Remote Assessments" (PI 056-1) and "Aide Memoire on Remote Assessments" (PI 057-1). These documents will enter into force on 1 January 2025.

The PIC/S states that the remote assessment and hybrid inspection will have a place in an inspector‘s toolkit beyond the pandemic.

They soon will be available in our GMP knowledge portal, the GMP Compliance Adviser.

Guidance on remote assessments
The guidance distinguishes between fully interactive remote assessments, partially interactive remote assessments, desktop assessments, and hybrid inspections.
It covers the logistics and the technical requirements for remote inspections.

A feasibility check for a remote inspection using a risk assessment is mandatory. Factors to be considered include:

  • Previous inspection history
  • Activities carried out at site
  • Length of time since last on-site inspection
  • Information relating to the site from any regulatory authority / source
  • Changes since last inspection
  • Internet connectivity of site and of inspectors

Documentation requirements are also given. For example, the GMP certificate should clearly state whether the assessment/inspection was performed remotely, on-site or hybrid.

Aide Memoire on remote inspections
The Aide Memoire provides best practices and summaries for preparing and conducting remote assessments and post-inspection activities. It also provides prompts and questions to guide users through these processes.
Issues raised include, for example:

  • Pre-inspection teleconference with the site
  • Secure platform for sharing documents
  • Connectivity test
  • Need for an independent translator
  • Daily tentative schedule to ensure the availability of subject matter exterts (SMEs)
  • Site tours?
  • What type of document will be issued after the remote assessment

Source:

PIC/S: News

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next